Immunology / Virology & Vaccines

Older adult receiving vaccine
#Covid-19 #Immunity #Immunology / Virology & Vaccines #Influenza #University of Oxford

Collaborative study to improve flu and Covid-19 vaccine design

With funding from MRC/UKRI, the University of Oxford has assembled a team of scientists, radiologists and clinicians to research and understand the cause and effect of varying responses to vaccination. The results will assist researchers in designing vaccines which will offer greater protection to the most… Read More

#News

Doctor looks at x-ray of the lungs
#Clinical trial #Drug delivery #Immunology / Virology & Vaccines #TB #TB vaccine #University of Oxford

Clinical trial will test novel inhaled TB vaccine

A new study will compare whether giving tuberculosis vaccine by inhalation is better at protecting against tuberculosis (TB) than injection into the skin. The Jenner Institute at the University of Oxford is conducting the study using Bacille Calmette-Guérin (BCG), the current licensed vaccine against TB. Read More

#News

Conference microphone
#Events #Immunology / Virology & Vaccines #Nanomedicine / nanotechnology #NIAID #SLAS2024

SLAS2024 update: The technology behind nanoparticle-based vaccines

Will you be attending SLAS2024 in Boston? This year the programme will feature a track curated by DDW taking place in the Ignite Theater ‘Innovation & technology: from lab to patient’. Co-sponsored by Integra Biosciences and Hamamatsu Corporation, the Ignite Theater will be… Read More

#News

Patient receiving a vaccine
#Covid-19 #Covid-19 vaccine #Immunology / Virology & Vaccines #Long Covid

Covid-19 vaccines found to protect against long Covid

A study has revealed that Covid-19 vaccines are effective in preventing long Covid, but the BioNTech/Pfizer vaccine provided better protection than ChAdOx1, developed by Oxford University/AstraZeneca. A research team at NDORMS (Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences), University of Oxford has found that vaccination… Read More

#News #Trending News

Patient receiving vaccine
#CEPI #Immunology / Virology & Vaccines #Nipah Virus #Pandemic prevention #University of Oxford

In-human trial begins for first potential Nipah virus vaccine

The first clinical trial participants have received doses of the ChAdOx1 NipahB vaccine at the University of Oxford. Nipah virus is mostly found in South-East Asia that can be fatal in up to 75% of cases. Despite the first outbreaks occurring 25 years ago in… Read More

#News

Scientific technology
#AI / data analytics / healthtech / informatics #Clinical development #Data automation #Data management #Diagnostics #Drug discovery #Electronic Lab Notebooks (ELN) #FAIR Principles #Genomics #Immunology / Virology & Vaccines #Infectious diseases #Informatics #mRNA #Personalised medicine #Precision medicine #Predictive diagnostics #Public health

New podcast: Revolutionary technology for drug discovery

This is the latest episode of the free DDW narrated podcast, titled “Revolutionary technology for drug discovery and development” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: mRNA technology may hold the future for a cytomegalovirus vaccine; … Read More

#News

Doctor prepares vaccine
#Barinthus Biotherapeutics #CEPI #Immunology / Virology & Vaccines #Partnership #University of Oxford

Partnership to fast-track MERS vaccine

UK-based Barinthus Biotherapeutics, the Coalition for Epidemic Preparedness Innovations (CEPI) and the University of Oxford are working together to fast-track the development of a vaccine candidate for the prevention of Middle East Respiratory Syndrome (MERS). The partners plan to take a MERS vaccine from early development through Phase II clinical… Read More

#Business & Investment #News

#Cancer research #Clinical trials #Covid-19 #Immunology / Virology & Vaccines #Neuroscience #Oncology

DDW readers’ top drug discovery developments of 2023

DDW’s Diana Spencer takes a look at the breaking news stories that were most popular with DDW readers over the last year. Representing a dominant field of drug discovery, it isn’t surprising that breakthroughs in cancer research were popular with DDW readers in 2023, particularly strategies to overcome treatment resistance… Read More

#Exclusive Content

HIV cell
#HIV #Immunity #Immunology / Virology & Vaccines #National Institute of Allergy and Infectious Diseases

Study suggests ways to improve future HIV vaccine candidates

An effective HIV vaccine may need to prompt strong responses from CD8+ T cells to protect people from acquiring HIV, according to a study from the National Institute of Allergy and Infectious Diseases (NIAID). The researchers drew comparisons between the immune system activity of past HIV… Read More

#News

Doctor prepares vaccine
#Funding #Immunology #Immunology / Virology & Vaccines #Pandemic prevention #University of Oxford

University of Oxford receives £7.8 million to fight pandemic threats

The Oxford Vaccine Group (OVG), which led the development of the Oxford vaccine for Covid-19, has been awarded a total of £7.8 ($9.8) million by UK Aid for research into the prevention of five diseases with epidemic or pandemic potential. The awards will fund research into… Read More

#News

Vaccine development
#Bill & Melinda Gates Foundation #Funding #Immunology / Virology & Vaccines #Naobios #Omicron

Naobios receives $1.87 million in support of vaccine development 

Naobios, a CDMO providing bioprocess development and GMP production of clinical batches of virus-based products, has received a $1.87 million grant from the Bill & Melinda Gates Foundation in support of vaccine development.   Naobios will manufacture a human viral challenge agent that will be used to evaluate… Read More

#News

Vaccine research
#Assays #Covid-19 #Drug efficacy #eBook #Immunology / Virology & Vaccines #Vaccines

eBook: Assessing the efficacy of vaccines through laboratory assays

The eighth eBook of the Hamilton series is now available to download for free. In ‘Assessing the Efficacy of Vaccines through Laboratory Assays‘, the authors discuss the key milestones achieved throughout the history of vaccine development, the laboratory tests commonly used to assess vaccines’ efficacy, and we… Read More

#News

#Assays #Covid-19 #Drug efficacy #Immunology / Virology & Vaccines #Vaccines

Assessing the efficacy of vaccines through laboratory assays

In the eighth eBook of the Hamilton series, ‘Assessing the Efficacy of Vaccines through Laboratory Assays’, we discuss: Vaccine development: Key milestones and impact of Covid-19 Laboratory tests commonly used to assess vaccines’ efficacy and the benefits of automating them Hamilton standardised and customised solutions for workflows such as qPCR,… Read More

#Resources

Covid-19 vaccine
#Covid-19 #Immunology / Virology & Vaccines #University of Queensland

Successful clinical trial for re-engineered Covid vaccine 

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The pivotal proof-of-concept testing clears the way to progress the Clamp2 technology in a range of research programmes.  … Read More

#Covid-19 #News

Genomic profiling
#Africa #Antibiotic resistance #Antimicrobial resistance (AMR) #Genetics / genomics #Immunology / Virology & Vaccines

Scientists use genomics to counter antimicrobial resistant typhoid

Genome sequencing has been used to study typhoid fever in a study in Zimbabwe and understand how the disease has evolved to be resistant to treatment. Typhoid fever claims over 135,000 lives annually. Treating it relies on antimicrobials but in the last couple of decades, antimicrobial… Read More

#News

Mosquito
#Chikungunya virus #FDA #Immunology / Virology & Vaccines #Valneva

FDA approves world’s first chikungunya vaccine

The US Food and Drug Administration (FDA) has approved Ixchiq, Valneva’s single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus (CHIKV). The vaccine is indicated in individuals 18 years of age and older who are at increased risk of exposure to CHIKV. Read More

#News #Trending News